Novagant Corp. (OTC: NVGT) -
July 16, 2014
Novagant introduces GoldenCBD™ edibles and ingestable
products line
GoldenCBD™ is 100% natural and derived from the
federally-legal industrial hemp plant
DENVER, CO – (July 16, 2014 - PR Newswire) - Novagant Corp. (OTC:
NVGT) is pleased to
announce that in this month of July it will release its GoldenCBD™ oil that will
be available in several forms, including capsules and liquids. It will be the
answer for those Medical Cannabis Patients living outside Washington and
Colorado.
Novagant’s GoldenCBD™, along with its GLAVAPE™ product, is proud to be the
finest, most consistent Cannabidiol (CBD)-rich hemp oil in the world. The
Company combined the power of natural hemp with the gift from mother nature to
scientifically formulated CBD-rich hemp oil.
GoldenCBD™ is 100% natural and derived from the federally-legal industrial hemp
plant. The Company’s unique hemp cultivars, combined with its proprietary
technologies, produce the highest quality CBD-rich hemp oil in the world.
GoldenCBD" is a mark of quality ensuring the highest quality as it is lab tested
multiple times during the manufacturing process, from seed to shelf. The Company
tests for CBD content, other cannabinoid content, yeast/mold/fungus, and
bacteria like E. coli to
ensure safety and quality.
The GoldenCBD™ is:
• A natural organic (non-synthetic), safe, and legal product.
• Non-psychoactive.
• 3%-20% CBD+ by volume.
• Decarboxylated and filtered.
• Made from Hemp Oil (Seed & Stalk).
• Is from non-GMO industrial hemp grown without pesticides, herbicides, or
chemical fertilizers.
• Is stringently lab tested for quality.
• Is independently certified.
“GoldenCBD™ is an important food supplement that is in dire need for those
living outside of Washington and Colorado.” Said Michael Thornton, VP at
Novagant.
Cannabidiol is looked to for its "potential as a treatment for a wide range of
conditions, including rheumatoid arthritis, diabetes, alcoholism, MS, chronic
pain, schizophrenia, PTSD, antibiotic-resistant infections, epilepsy, and other
neurological disorders." (http://www.projectcbd.org/about/introducing-cbd/)
About Novagant Corp.
Novagant Corp. was incorporated in the state of Nevada on February 23, 1987
under the name of Kendrex Systems, Inc. The Company underwent several name
changes, and ultimately on November 26, 2013 changed its name to Novagant, Inc.
For more information about the Company, please visit www.novagant.com.
Safe Harbor:
Statements in this press release may constitute forward-looking statements and
are subject to numerous risks and uncertainties, including the failure to
complete successfully the development of new or enhanced products, the Company's
future capital needs, the lack of market demand for any new or enhanced products
the Company may develop, any actions by the Company's affiliates that may be
adverse to the Company, the success of competitive products, other economic
factors affecting the Company and its markets, seasonal changes, and other risks
detailed from time to time in the Company's filings with the U.S. Securities and
Exchange Commission. The actual results may differ materially from those
contained in this press release. The Company disclaims any obligation to update
any statements in this press release.
Contact:
Novagant Corp.
office@novagant.com
SOURCE Novagant Corp.
Disclaimer
FN Media Group LLC (FNMG) owns and operates
FinancialNewsMedia.com (FNM)
which is a third party publisher that disseminates electronic information
through multiple online media channels. FNMG's intended purposes are to deliver
market updates and news alerts issued from private and publicly trading
companies as well as providing coverage and increased awareness for companies
that issue press to the public via online newswires. FNMG and its affiliated
companies are a news dissemination and financial marketing solutions provider
and are NOT a registered broker/dealer/analyst/adviser, holds no investment
licenses and may NOT sell, offer to sell or offer to buy any security. FNMG's
market updates, news alerts and corporate profiles are NOT a solicitation or
recommendation to buy, sell or hold securities. The material in this release is
intended to be strictly informational and is NEVER to be construed or
interpreted as research material. All readers are strongly urged to perform
research and due diligence on their own and consult a licensed financial
professional before considering any level of investing in stocks. The companies
that are discussed in this release may or may not have approved the statements
made in this release. Information in this release is derived from a variety of
sources that may or may not include the referenced company's publicly
disseminated information. The accuracy or completeness of the information is not
warranted and is only as reliable as the sources from which it was obtained.
While this information is believed to be reliable, such reliability cannot be
guaranteed. FNMG disclaims any and all liability as to the completeness or
accuracy of the information contained and any omissions of material fact in this
release. This release may contain technical inaccuracies or typographical
errors. It is strongly recommended that any purchase or sale decision be
discussed with a financial adviser, or a broker-dealer, or a member of any
financial regulatory bodies. Investment in the securities of the companies
discussed in this release is highly speculative and carries a high degree of
risk. FNMG is not liable for any investment decisions by its readers or
subscribers. Investors are cautioned that they may lose all or a portion of
their investment when investing in stocks. This release is not without bias, and
is considered a conflict of interest if compensation has been received by FNMG
for its dissemination. To comply with Section 17(b) of the Securities Act of
1933, FNMG shall always disclose any compensation it has received, or expects to
receive in the future, for the dissemination of the information found herein on
behalf of one or more of the companies mentioned in this release. For current
services performed FNMG has been compensated one thousand four hundred dollars
for news coverage of the current press release issued by Novagant Corp. by a
non-affiliated third party.
This release contains "forward-looking statements" within the meaning of Section
27A of the Securities Act of 1933, as amended, and Section 21E the Securities
Exchange Act of 1934, as amended and such forward-looking statements are made
pursuant to the safe harbor provisions of the Private Securities Litigation
Reform Act of 1995. "Forward-looking statements" describe future expectations,
plans, results, or strategies and are generally preceded by words such as "may",
"future", "plan" or "planned", "will" or "should", "expected," "anticipates",
"draft", "eventually" or "projected". You are cautioned that such statements are
subject to a multitude of risks and uncertainties that could cause future
circumstances, events, or results to differ materially from those projected in
the forward-looking statements, including the risks that actual results may
differ materially from those projected in the forward-looking statements as a
result of various factors, and other risks identified in a company's annual
report on Form 10-K or 10-KSB and other filings made by such company with the
Securities and Exchange Commission. You should consider these factors in
evaluating the forward-looking statements included herein, and not place undue
reliance on such statements. The forward-looking statements in this release are
made as of the date hereof and FNMG undertakes no obligation to update such
statements.
|